06247nam 2201573z- 450 991058021580332120231214133001.0(CKB)5690000000011929(oapen)https://directory.doabooks.org/handle/20.500.12854/87543(EXLCZ)99569000000001192920202207d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierNanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to BedsideBaselMDPI - Multidisciplinary Digital Publishing Institute20221 electronic resource (296 p.)3-0365-4490-9 3-0365-4489-5 Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations.Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of DiseaseTechnology: general issuesbicsscHistory of engineering & technologybicsscMaterials sciencebicsscpoly(lactic-co-glycolic acid) (PLGA)blood–brain barrier (BBB)current Good Manufacturing Practice (cGMP)Food and Drug Administration (FDA)nanotechnologyPLGA nanoparticlesneurodegenerative diseasesdrug deliverycentral nervous systemneuroprotective drugsfluorescent labelingDiIcoumarin 6rhodamine 123Cy5.5quantum yieldbrightnessstability of fluorescent labelconfocal microscopyintracellular internalizationin vivo neuroimagingdouble-emulsion methoddry powder inhalationantigen releaseporous PLGA particlesmicrofluidicsmethotrexatechitosanPLA/PLGAsustained releasemicro-implantanimal modelminimally invasivedrug delivery systemnanoparticlespoly (lactic-co-glycolic acid) (PLGA)microfluidicpharmacokinetics (PK) and biodistributionatorvastatin calciumpoly(lactide-co-glycolide)polymeric nanoparticlescarrageenan induced inflammationanti-inflammatoryradiolabeled nanoparticlesnuclear medicinephotothermal therapyphthalocyanineSKOVip-katKatushkaTurboFP635JO-4PLGAorthotopic tumors3D culturespheroidspoly(lactic-co-glycolic acid)nanomedicinescale-up manufacturingclinical translationinline sonicationtangential flow filtrationlyophilizationdownstream processingH. pyloridesign of experimentspoly(lactic-co-glycolic) acidsizecancerchemoimmunotherapyimmunogenic cell deathimmune checkpoint blockadePNA5 glycopeptidemas receptorangiotensinPLGA diblock copolymerester and acid-end cappeddouble emulsion solvent evaporationbiocompatiblebiodegradablecardiovascularnanoparticlesolid-state characterizationin vitrodrug release kinetics modelingPEGylationamineemulsionpolyvinyl alcohol (PVA)Pluronic triblock copolymertrehalosesucroseIndomethacinsolventsstabilizersmorphologyparticle-sizeencapsulationdrug releasecytotoxicityTechnology: general issuesHistory of engineering & technologyMaterials scienceTagit Oyaedt1313404Tagit OyaothBOOK9910580215803321Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside3031389UNINA